Global Oncology Partnering Research Report 2023: Trends, Players and Financials for 6,400+ Deals Signed Since 2016

News provided by

Jun 27, 2023, 21:00 ET

DUBLIN, June 27, 2023 /PRNewswire/ -- The "Global Oncology Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of all oncology partnering deals announced since 2016 including financial terms where available including over 6,400 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering oncology deals.

The report presents financial deal terms values for oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of oncology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in oncology dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading oncology deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active oncology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to oncology deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all oncology partnering deals by specific oncology target announced since 2016. The chapter is organized by specific oncology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all oncology partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2016.

Report scope

Global Oncology Partnering 2016-2023: Deal trends, players and financials includes:

Trends in oncology dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to over 6,400 oncology deal records
The leading oncology deals by value since 2016

In Global Oncology Partnering 2016-2023: Deal trends, players and financials, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication

Chapter 3 -Financial deal terms for oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers
4.1. Introduction
4.2. Most active in oncology partnering
4.3. List of most active dealmakers in oncology
4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by oncology therapeutic target

Appendices
Appendix 1 - Directory of oncology deals by company A-Z since 2016
Appendix 2 - Directory of oncology deals by deal type since 2016
Appendix 3 - Directory of oncology deals by stage of development since 2016
Appendix 4 - Directory of oncology deals by technology type since 2016
Further reading on dealmaking
Deal type definitions

Table of figures
Figure 1: Oncology partnering since 2016
Figure 2: Oncology partnering by deal type since 2016
Figure 3: Oncology partnering by industry sector since 2016
Figure 4: Oncology partnering by stage of development since 2016
Figure 5: Oncology partnering by technology type since 2016
Figure 6: Oncology partnering by indication since 2016
Figure 7: Oncology deals with a headline value
Figure 8: Oncology deals with upfront payment values
Figure 9: Oncology deals with milestone payment
Figure 10: Oncology deals with royalty rates
Figure 11: Active oncology dealmaking activity since 2016
Figure 12: Top oncology deals by value since 2016

Companies Mentioned

1ST Biotherapeutics
2bPrecise
2cureX
2seventy bio
2X Oncology
3B Pharmaceuticals
3D Medicines
3P Biopharmaceuticals
3SBio
4baseCare
4C Biomed
4D Path
4D Pharma
5AM Ventures
7 Hills Pharma
9 Meters Biopharma
48Hour Discovery
111
1717 Life Science Ventures
A*STAR Bioinformatics Institute
A*STAR Singapore Immunology Network
A*STAR' Institute of Molecular and Cell Biology
A-Alpha Bio
A2 Biotherapeutics
A2A Pharmaceuticals
Aadi Bioscience
Aarvik Therapeutics
Abbisko Therapeutics
Abbvie
Abcam
AbCellera
Abcuro
Abdul Latif Jameel Health
Abexxa Biologics
Abilita Bio
Abingworth Management
Abintus Bio
Ablaze Pharmaceuticals
ABL Bio
Ab Magnitude Ventures
Abound Bio
Abpro
Abramson Cancer Center
AbSci
ABVC BioPharma
Abveris
ABX
Abzena
Academia Sinica
Academic and Community Cancer Research United
AC Bioscience
Accelerate Brain Cancer Cure
Accent Therapeutics
Accenture
Access to Comprehensive Genomic Profiling Coalition
Accord Healthcare
Accudata Systems
Accuray
ACEA Biosciences
ACEA Therapeutics
Acentrus Specialty
Acepodia
Acerand Therapeutics
Acerta Pharma
Aceso Life Science
Achilles Therapeutics
Acibadem University
Acino Pharma
Acoustic MedSystems
Acrivon Therapeutics
Acrotech Biopharma
Actelion
ACT Genomics
Actimed Therapeutics
Actinium Pharmaceuticals
Actuate Therapeutics
Actym Therapeutics
Acucela
Acuitas Therapeutics
Acuity Pharmaceuticals
Acupath Laboratories
Adagene
AdAlta
Adamis Pharmaceuticals
Adaptate Biotherapeutics
Adaptiiv
Adaptimmune
Adaptive Biotechnologies
AdaptVac
ADC Therapeutics
Addario Lung Cancer Medical Institute
Adgero Biopharmaceuticals
Adicet Bio
ADIENNE Pharma & Biotech
Adimab
Adium Pharma
Adlai Nortye
AdoRx Therapeutics
ADT Pharmaceuticals
Adult Brain Tumor Consortium
Aduro BioTech
Advaite
AdvaMed
Advanced Accelerator Applications
Advanced BioScience Laboratories
Advanced Dermatology and Cosmetic Surgery Group
Advanced Nuclear Medicine Ingredients
Advanced Proteome Therapeutics
Advanced Radiation Therapy
Advanz Pharma
Advaxis
Aeglea BioTherapeutics
Aerpio Pharmaceuticals
Aethlon Medical
Aetion
Aetna
AffaMed Therapeutics
Affigen
Affimed Therapeutics
Affinia Therapeutics
Again Life Italia
Agalimmune
AGC Biologics
Agena Bioscience
Agencja Badan Medycznych
Agendia
Agenus Bio
AgeX Therapeutics
Agilent Technologies
Agilvax
Agios Pharmaceuticals
AG Mednet
AgonOx
AiCure
Aidence
Aidoc
Aiforia Technologies
AIkido Pharma
Aileron Therapeutics
AimedBio
AIMM Therapeutics
Aion Therapeutic
AirXpanders
Ajax Therapeutics
Ajinomoto
Akeso Biopharma
Akoya Biosciences
Akrevia Therapeutics
AKSO Biopharmaceutical
Albany Medical College
Albert Einstein College of Medicine
Alcami
Alcedis
Alchemab
Aldevron
Alector
Aleta Biotherapeutics
Alex's Lemonade Stand Foundation
Alibaba Health
Alkermes

For more information about this report visit https://www.researchandmarkets.com/r/ggo01h

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets